Table 4.
Relationships between clinicopathological characteristics and pathological response evaluated by CAP-TRG system
| Characteristics | Total cases (n = 192), no. (%) | CAP-TRG | P value | |||
|---|---|---|---|---|---|---|
| 0 (n = 11), no. (%) | 1 (n = 23), no. (%) | 2 (n = 40), no. (%) | 3 (n = 118), no. (%) | |||
| Gender | 0.134 | |||||
| Male | 139 (72.4) | 10 (7.2) | 20 (14.4) | 29 (20.9) | 80 (57.6) | |
| Female | 53 (27.6) | 1 (1.9) | 3 (5.7) | 11 (20.8) | 38 (71.7) | |
| Age | 0.880 | |||||
| < 55y | 89 (46.4) | 6 (6.7) | 10 (11.2) | 17 (19.1) | 56 (62.9) | |
| ≥ 55y | 103 (53.6) | 5 (4.9) | 13 (12.6) | 23 (22.3) | 62 (60.2) | |
| Location | 0.525 | |||||
| Esophagogastric junction | 44 (22.9) | 1 (2.3) | 4 (9.1) | 8 (18.2) | 31 (70.5) | |
| Proximal gastric | 71 (37) | 7 (9.9) | 8 (11.3) | 15 (21.1) | 41 (57.7) | |
| Distal gastric | 77 (40.1) | 3 (3.9) | 11 (14.3) | 17 (22.1) | 46 (59.7) | |
| Maximal diameter of tumor bed | 0.013 | |||||
| < 4.5 cm | 108 (56.2) | 9 (8.3) | 20 (18.5) | 20 (18.5) | 59 (54.6) | |
| 4.5–8 cm | 64 (33.3) | 1 (1.6) | 3 (4.7) | 17 (26.6) | 43 (67.2) | |
| > 8 cm | 20 (10.4) | 1 (5) | 0 (0) | 3 (15) | 16 (80) | |
| Histological differentiation | 0.002 | |||||
| Well-moderate | 45 (23.4) | 4 (8.9) | 12 (26.7) | 9 (20) | 20 (44.4) | |
| Poor | 147 (76.6) | 7 (4.8) | 11 (7.5) | 31 (21.1) | 98 (66.7) | |
| Laurén classification | 0.143 | |||||
| Intestinal | 77 (40.1) | 4 (5.2) | 14 (18.2) | 14 (19.2) | 47 (64.4) | |
| Diffuse | 73 (38) | 7 (9.6) | 5 (6.8) | 10 (23.8) | 28 (66.7) | |
| Mixed | 42 (21.9) | 0 (0) | 4 (9.5) | 15 (35.7) | 23 (54.8) | |
| LVI | <0.001 | |||||
| Negative | 94 (49) | 11 (11.7) | 19 (20.2) | 28 (29.8) | 36 (38.3) | |
| Positive | 98 (51) | 0 (0) | 4 (4.1) | 12 (12.2) | 82 (83.7) | |
| PNI | <0.001 | |||||
| Negative | 76 (39.6) | 11 (14.5) | 22 (28.9) | 13 (17.1) | 30 (39.5) | |
| Positive | 116 (60.4) | 0 (0) | 1 (0.9) | 27 (23.3) | 88 (75.9) | |
| AJCC ypT category | <0.001 | |||||
| 0 | 11 (5.7) | 11 (100) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 20 (10.4) | 0 (0) | 12 (60) | 5 (25) | 3 (15) | |
| 2 | 23 (12) | 0 (0) | 5 (21.7) | 6 (26.1) | 12 (52.2) | |
| 3 | 57 (29.7) | 0 (0) | 5 (8.8) | 18 (31.6) | 34 (59.6) | |
| 4 | 81 (42.2) | 0 (0) | 1 (1.2) | 11 (13.6) | 69 (85.2) | |
| AJCC ypN category | <0.001 | |||||
| 0 | 55 (28.6) | 9 (16.4) | 13 (23.6) | 17 (30.9) | 16 (29.1) | |
| 1 | 36 (18.8) | 0 (0) | 6 (16.7) | 7 (19.4) | 23 (63.9) | |
| 2 | 50 (26) | 0 (0) | 3 (6) | 10 (20) | 37 (74) | |
| 3 | 51 (26.6) | 2 (3.9) | 1 (2) | 6 (11.8) | 42 (82.4) | |
| AJCC stage | <0.001 | |||||
| 0 | 9 (4.7) | 9 (100) | 0 (0) | 0 (0) | 0 (0) | |
| 1 | 24 (12.5) | 0 (0) | 14 (58.3) | 7 (29.2) | 3 (12.5) | |
| 2 | 53 (27.6) | 2 (3.8) | 6 (11.3) | 14 (26.4) | 31 (58.5) | |
| 3 | 106 (55.2) | 0 (0) | 3 (2.8) | 19 (17.9) | 84 (79.2) | |
| R0 resection | 0.212 | |||||
| Yes | 159 (82.8) | 11 (6.9) | 20 (12.6) | 35 (22) | 93 (58.5) | |
| No | 33 (17.2) | 0 (0) | 3 (9.1) | 5 (15.2) | 25 (75.8) | |
| Adjuvant chemotherapy | 0.69 | |||||
| Not received | 59 (30.7) | 3 (5.1) | 6 (10.2) | 10 (16.9) | 40 (67.8) | |
| Received | 133 (69.3) | 8 (6) | 17 (35.3) | 30 (22.6) | 78 (58.6) | |